AVEO: Data Provides Rationale For Investigation Of AV-203 As Anticancer Therapy

By RTT News, 
A A A


(RTTNews.com) - AVEO Oncology ( AVEO ) announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO's ErbB3 (HER3) inhibitory antibody candidate. The company said the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy.

The recommended Phase 2 dose was established at 20mg/kg intravenously every 2 weeks. No anti-drug antibodies were detected, and pharmacokinetic results indicated a dose-proportional increase in levels of AV-203.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com



This article appears in: Technology

Referenced Stocks: AVEO

RTT News


More from RTT News:

Related Videos

The Pumpkin Carvers
The Pumpkin Carvers                 

Stocks

Referenced

Most Active by Volume

88,066,694
  • $97.19 ▲ 2.61%
58,241,731
  • $71.29 ▲ 2.92%
51,058,864
  • $44.87 ▲ 0.09%
48,927,829
  • $28.75 ▲ 0.81%
46,551,917
    $15.52 unch
40,249,498
  • $3.46 ▼ 0.57%
38,633,031
  • $22.43 ▼ 9.63%
38,240,825
  • $34.71 ▲ 3.30%
As of 7/23/2014, 04:04 PM